Improving Asthma Control for a Reduced Carbon Footprint

MHP Group

Inhalers are crucial for managing the one million asthma

attacks suffered by UK adults each year. However, the propellants used in some inhalers are a small but important contributor to greenhouse gas emissions. AstraZeneca launched its pioneering The CARBON programme which aims to calculate the impact of poor disease control and disease progression on the carbon footprint of respiratory care. The programme aims to highlight how guideline implementation and better management can drive improvements in patient care and reduce the carbon footprint of respiratory care. The campaign helped galvanise a sector-wide response and secure endorsements for AstraZeneca’s leadership role.